Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-15
2008-11-25
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S419000, C514S422000, C514S428000, C548S494000, C548S517000, C548S566000
Reexamination Certificate
active
07456209
ABSTRACT:
IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kdof less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.
REFERENCES:
patent: 3832253 (1974-08-01), DiPalma et al.
patent: 3854480 (1974-12-01), Zaffaroni
patent: 4278793 (1981-07-01), Durckheimer et al.
patent: 4452775 (1984-06-01), Kent
patent: 4667014 (1987-05-01), Nestor, Jr. et al.
patent: 4748034 (1988-05-01), De Rham
patent: 5075109 (1991-12-01), Tice et al.
patent: 5239660 (1993-08-01), Ooi
patent: 5660811 (1997-08-01), Mills
patent: 5766572 (1998-06-01), Hasegawa et al.
patent: 6110691 (2000-08-01), Wang et al.
patent: 6133437 (2000-10-01), Korneluk et al.
patent: 6187557 (2001-02-01), Rothe et al.
patent: 6338835 (2002-01-01), Shochat et al.
patent: 6608026 (2003-08-01), Wang
patent: 6911426 (2005-06-01), Reed et al.
patent: 6992063 (2006-01-01), Shi
patent: 7244851 (2007-07-01), Cohen et al.
patent: 2002/0132786 (2002-09-01), Alnemri et al.
patent: 2002/0160975 (2002-10-01), Alnemri
patent: 2002/0177557 (2002-11-01), Shi
patent: 2004/0054148 (2004-03-01), Alnemri
patent: 2005/0197403 (2005-09-01), Harran et al.
patent: 2005/0234042 (2005-10-01), Palermo et al.
patent: 2005/0261203 (2005-11-01), Cohen et al.
patent: 2006/0014700 (2006-01-01), Cohen et al.
patent: 2006/0025347 (2006-02-01), Condon et al.
patent: 2006/0052311 (2006-03-01), Sharma et al.
patent: 2006/0128632 (2006-06-01), Sharma et al.
patent: 2006/0167066 (2006-07-01), Cohen et al.
patent: 2006/0194741 (2006-08-01), Condon et al.
patent: 2006/0258581 (2006-11-01), Reed et al.
patent: 2006/0264379 (2006-11-01), Jarvis et al.
patent: 2007/0003535 (2007-01-01), Reed et al.
patent: 2007/0042428 (2007-02-01), Springs et al.
patent: 2007/0093428 (2007-04-01), Laurent
patent: 2007/0093429 (2007-04-01), Laurent et al.
patent: WO 99/15657 (1999-04-01), None
patent: WO 02/16418 (2002-02-01), None
patent: WO 02/26775 (2002-04-01), None
patent: WO 02/30959 (2002-04-01), None
patent: WO 02/096930 (2002-12-01), None
patent: WO 03/018014 (2003-03-01), None
patent: WO 2004/005248 (2004-01-01), None
patent: WO 2004/007529 (2004-01-01), None
patent: WO2004005248 (2004-01-01), None
patent: WO 2004/072105 (2004-08-01), None
patent: WO 2005/069888 (2005-08-01), None
patent: WO 2005/069894 (2005-08-01), None
patent: WO 2005/078989 (2005-08-01), None
patent: WO 2005/084317 (2005-09-01), None
patent: WO 2005/094818 (2005-10-01), None
patent: WO 2005/097791 (2005-10-01), None
patent: WO 2006/010118 (2006-01-01), None
patent: WO 2006/014361 (2006-02-01), None
patent: WO 2006/017295 (2006-02-01), None
patent: WO 2006/020060 (2006-02-01), None
patent: WO 2006/069063 (2006-06-01), None
patent: WO 2006/091972 (2006-08-01), None
patent: WO 2006/122408 (2006-11-01), None
patent: WO 2006/128455 (2006-12-01), None
patent: WO 2006/133147 (2006-12-01), None
patent: WO 2007/101347 (2007-09-01), None
patent: WO 2007/106192 (2007-09-01), None
patent: WO 2007/130626 (2007-11-01), None
Macor et al., The Synthesis of a Conformationally Restricted Analog of the Anti-Migraine Drug Sumatriptan, 1992, Tetrahedron Lett. 33(52):8011-8014.
Chawla-Sarkar, Preferential Induction of Apoptosis by Interferon (IFN)-β Compared with IFN-α2: Correlation with TRAIL/Apo2L Induction in Melanoma Cell Lines, 2001, Clin. Can. Res. 7:1821-1831.
Sun et al., Structure-based Design of Potent, Conformationally Constrained Smac Mimetics, 2004, J. Am. Chem. Soc. 126:16686-16687.
Park et al., Non-peptide small molecule inhibitors of XIAP, 2004, Bioorganic & Med. Chem. Lett. 15:771-775.
Lang's Handbook of Chemistry, Dean ed., Table 7-2, 1985.
Fulda et al., Smac agonists sensitized for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of Malignant glioma in vivo, 2002, Nat. Med. 8(8):808-815.
Wu et al., Structural Analysis of a Functional DIAP1 Fragment Bound to Grim and Hid Peptides, 2001, Mol. Cell 8:95-104.
Oost et al., Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer, 2004, J. Med. Chem. 47:4417-4426.
Chai et al., Structural and biochemical basis of apoptotic activation by Smac/DIABLO, 2000, Nature 406:855-862.
Ambrosini et al., Induction of Apoptosis and Inhibition of Cell Proliferation by survivin Gene Targeting, 1998, J. Biol. Chem. 273(18):11177-11182.
Ripka et al., Peptidomimetic design, 1998, Curr. Op. Chem. Biol. 2:441-452.
Hruby et al., Synthesis of oligopeptide and peptidomimetic libraries, 1997, Curr. Op. Chem. Biol. 1:114-119.
Hruby et al., Conformational and Topographical Considerations in Designing Agonist Peptidomimetics from Peptide Leads, 2000, Curr. Med. Chem. 9:945-970.
Wyllie et al., Cell Death: the significance of apoptosis, 1980, Int. Rev. Cytol. 68:251-306.
Wyllie, Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation, 1981, Nature 284:555-556.
Gennaro, Remington's Pharmaceutical Sciences, Mack Publ. Co., Easton, PA (TOC).
Craig et al., Modern Pharmacology with Clinical Applications, 6thed., Kerins ed., Ch. 56:639-656.
Hay, Understanding IAP function and regulation: a view fromDrosophila, 2000, Cell Death and Diff. 7:1045-1056.
Chan et al., Fmoc Solid Phase Peptide Synthesis: A Practical Approach, 2000, Oxford University Press (TOC).
Boxrud et al., Streptokinase Binds to Human Plasmin with High Affinity, Perturbs the Plasmin Active Site, and Induces Expression of a Substrate Recognition Exosite for Plasminogen, 2000, J. Biol. Chem. 275(19):14579-14589.
Owenius et al., Properties of Spin and Fluorescent Labels at a Receptor-Ligand Interface, 1999, Biophys. J. 77:2237-2250.
Hiratsuka, ATP-induces Opposite Changes in the Local Environments around Cys697(SH2) and Cys707(SH1) of the Myosin Motor Domain Revealed by the Prodan Fluorescence, 1999, J. Biol. Chem. 274(41):29156-29163.
Wu et al., Structural basis of IAP recognition by Smac/DIALBO, 2000, Nature 408:1008-1012.
Brunger, X-PLOR, a System for Crystallography and NMR, Yale University Press, New Haven, CT, 1991.
Chen et al., Grim, a novel cell death gene inDrospohila, 1996, Genes & Devel. 10:1773-1782.
Goyal et al., Induction of apoptosis byDrosophilareaper, hid and grim through inhibition of IAP function, 2000, Embo J. 19(4):589-597.
Jones et al., Improved methods for building protein models in electron density maps and the location of errors in these models, 1991, Acta Crystallogr. A47:110-119.
Kraulis, Molscript: a program to produce both detailed and schematic plots of protein structures, 1991, J. Appl. Crystallogr. 24:946-950.
Lisi et al., Diverse Domains of THREAD/DIAPI are Required to Inhibit Apoptosis Induced by REAPER and HID inDrosophila, 1999, Genetics Soc. Am. 154:669-678.
Liu, Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain, Dec. 2000, Nature, pp. 1004-1008.
McCarthy et al., Apoptosis induced byDrosophilareaper and grim in a human system, 1999, J. Biol. Chem. 273(37):24009-24015.
Morgan et al., Approaches to the Discovery of Non-Peptide Ligands for Peptide Receptors and Peptidases. 1989, Ann. Rep. Med. Chem. 243-252.
Navaza, AmoRe: an Automated Package for Molecular Replacement, 1994, Acta Cryst. A50:157-163.
Nicholls et al., Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons, 1991, Proteins: Struct. Funct. & Genet. 11:281-296.
Srinivasa et al., A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis, 2001, Nature 410:112-116.
Sun et al., NMR Structure and Mutagenesis of the Third Bir Domain of the Inhibitor Apoptosis Protein XIAP, 2000, J. Biol. Chem. 275(43):33777-33781.
Terwilliger et al., The CCP4 suite: Programs for protein crystallography, 1994, Acta Crystallogr. D50:760-763.
Terwilliger et al., Correlated Phasing of Multiple Isomorphous Replacement Data, 1996, Acta Crystall
Condon Stephen M.
Deng Yijun
LaPorte Matthew G.
Rippin Susan R.
Banner & Witcoff , Ltd.
Shiao Rei-tsang
Tetralogic Pharmaceuticals Corporation
LandOfFree
IAP binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IAP binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IAP binding compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4037394